Volume | 1,676 |
|
|||||
News | - | ||||||
Day High | 22.46 | Low High |
|||||
Day Low | 22.18 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Landos Biopharma Inc | LABP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
22.46 | 22.18 | 22.46 | 22.30 | 22.4799 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
50 | 1,676 | US$ 22.31 | US$ 37,398 | - | 2.50 - 22.84 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 5 | US$ 22.31 | USD |
Landos Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
69.5M | 3.12M | - | 0 | -21.94M | -7.04 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Landos Biopharma News
Date | Time | Source | News Article |
---|---|---|---|
3/25/2024 | 07:31 | PR Newswire (US) | AbbVie to Acquire Landos Biopharma, Further Strengthening.. |
3/25/2024 | 07:30 | GlobeNewswire Inc. | AbbVie to Acquire Landos Biopharma, Further Strengthening.. |
3/04/2024 | 15:14 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
3/04/2024 | 15:06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/14/2024 | 15:01 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
1/04/2024 | 07:05 | Edgar (US Regulatory) | Form 8-K - Current report |
11/21/2023 | 07:08 | Edgar (US Regulatory) | Form 8-K - Current report |
11/09/2023 | 07:22 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
11/09/2023 | 07:08 | Edgar (US Regulatory) | Form 8-K - Current report |
9/21/2023 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
9/14/2023 | 07:11 | Edgar (US Regulatory) | Form 8-K - Current report |
8/09/2023 | 07:18 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LABP Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.90 | 22.84 | 21.90 | 22.28 | 8,215 | 0.40 | 1.83% |
1 Month | 21.60 | 22.84 | 21.43 | 21.65 | 18,812 | 0.70 | 3.24% |
3 Months | 5.45 | 22.84 | 4.83 | 17.61 | 26,335 | 16.85 | 309.17% |
6 Months | 3.88 | 22.84 | 3.21 | 14.07 | 16,673 | 18.42 | 474.74% |
1 Year | 2.847 | 22.84 | 2.50 | 8.01 | 19,166 | 19.45 | 683.28% |
3 Years | 114.40 | 161.70 | 2.111 | 19.23 | 126,794 | -92.10 | -80.51% |
5 Years | 130.00 | 169.89 | 2.111 | 34.42 | 136,322 | -107.70 | -82.85% |
Landos Biopharma Description
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need. |